Lonza Group AG

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

If it's stability you're looking for, probably so.

Should You Have Lonza Stock on Your Watchlist?

Lonza enjoys an excellent brand reputation in the pharmaceutical industry. This leads to a premium valuation, and even after selling a lower-margin division, the valuation is quite high.

Lonza Group: Moving To A Net Cash Position

Lonza has appointed former Novartis executive Philippe Deecke as its new Chief Financial Officer, the Swiss chemicals company said on Thursday.

Lonza appoints Novartis executive as new Chief Financial Officer

Lonza Group AG (LZAGY) CEO Pierre-Alain Ruffieux on Q2 2021 Results - Earnings Call Transcript

Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lonza Group Ag (LZAGY) Upgraded to Buy: What Does It Mean for the Stock?

Infineon Technologies AG

Koninklijke KPN NV

Logitech

Prosus NV

Schneider Electric SE

Siemens Healthineers AG

Rentokil Initial PLC

The stocks could turn out to be winners in coming months if analysts' upbeat calls turn out to be correct.

12 European Stocks That Analysts Love and Investors Are Ignoring

aTyr Pharma

aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer. Under the terms of the agreement, Lonza will utilize its Ibex Design to manufacture material for ATYR2810.

aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810

Lonza Group Ltd (LZAGY) CEO Pierre-Alain Ruffieux on Q4 2020 Results - Earnings Call Transcript

Lonza Group is the second deep dive in my CDMO industry series. The company prospered in 2020 and will narrow its focus in 2021.

Lonza: Riding The Big Pharma Wave

Swiss contract drug maker Lonza has shortlisted German chemicals group Lanxess and private equity groups in the sale of its Lonza Specialty Ingredients (LSI) unit worth more than 3 billion Swiss francs ($3.38 billion), people close to the matter said.

Lonza shortlists Lanxess, private equity in unit sale, sources say

Green Thumb Industries Inc.

Nintendo

Tencent Holdings Limited

In a period of high uncertainty, OTC stocks can provide some great money-making opportunities for investors. Here are the top 7 stocks that are worth your time.

7 OTC Stocks That Should Be on Your Radar

AstraZeneca

BioNTech SE

Catalent

Emergent BioSolutions

Johnson & Johnson

Moderna

Novavax

Pfizer

The Race To Erase COVID-19

Lonza Group Ag (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lonza Group Ag (LZAGY) Moves to Buy: Rationale Behind the Upgrade

Pierre-Alain Ruffieux will lead the contract development and manufacturing organization.

News for Lonza Group AG Stock (LZAGY)